1
/
of
1
Gefitero (Gefitinib)
Gefitero (Gefitinib)
Regular price
₱45,000.00 PHP
Regular price
Sale price
₱45,000.00 PHP
Unit price
₱1,500.00 each
Taxes included.
Quantity
Couldn't load pickup availability
Gefitero (Gefitinib) is an oral tyrosine kinase inhibitor (TKI) designed for patients with specific types of non-small cell lung cancer (NSCLC). This prescription medication targets epidermal growth factor receptor (EGFR) mutations, making it a cornerstone therapy for EGFR-positive lung cancer management.
Gefitinib works by blocking EGFR signaling pathways that drive cancer cell growth and proliferation. It is indicated for first-line treatment of patients with metastatic NSCLC harboring EGFR-activating mutations, as well as for maintenance therapy after chemotherapy in patients with advanced disease. The medication has demonstrated significant improvements in progression-free survival and response rates in clinical trials.
This treatment is suitable for adult patients whose tumors exhibit sensitizing EGFR mutations (exon 19 deletions or exon 21 L858R substitutions). Gefitero offers a targeted approach with a favorable side effect profile compared to traditional chemotherapy, allowing patients to maintain quality of life while receiving effective cancer treatment.
The standard dosing regimen is 250 mg orally once daily. Gefitinib can be taken with or without food, and treatment typically continues until disease progression or unacceptable toxicity occurs. Regular monitoring through imaging and clinical assessment helps oncologists evaluate treatment response and adjust therapy as needed.
Common considerations include potential drug interactions, baseline liver and kidney function evaluation, and monitoring for interstitial lung disease or other serious adverse effects. Patients should maintain consistent communication with their healthcare provider throughout treatment to optimize outcomes and manage any side effects promptly.
Gefitero represents an important therapeutic option for eligible lung cancer patients, combining targeted efficacy with a manageable treatment profile for extended survival and disease control.
Gefitinib works by blocking EGFR signaling pathways that drive cancer cell growth and proliferation. It is indicated for first-line treatment of patients with metastatic NSCLC harboring EGFR-activating mutations, as well as for maintenance therapy after chemotherapy in patients with advanced disease. The medication has demonstrated significant improvements in progression-free survival and response rates in clinical trials.
This treatment is suitable for adult patients whose tumors exhibit sensitizing EGFR mutations (exon 19 deletions or exon 21 L858R substitutions). Gefitero offers a targeted approach with a favorable side effect profile compared to traditional chemotherapy, allowing patients to maintain quality of life while receiving effective cancer treatment.
The standard dosing regimen is 250 mg orally once daily. Gefitinib can be taken with or without food, and treatment typically continues until disease progression or unacceptable toxicity occurs. Regular monitoring through imaging and clinical assessment helps oncologists evaluate treatment response and adjust therapy as needed.
Common considerations include potential drug interactions, baseline liver and kidney function evaluation, and monitoring for interstitial lung disease or other serious adverse effects. Patients should maintain consistent communication with their healthcare provider throughout treatment to optimize outcomes and manage any side effects promptly.
Gefitero represents an important therapeutic option for eligible lung cancer patients, combining targeted efficacy with a manageable treatment profile for extended survival and disease control.
Share
